Calder Biosciences
New York, United States· Est. 2018
Conformationally locked best-in-class RSV & Universal Flu subunit vaccines
Private Company
Total funding raised: $16.8M
About
Conformationally locked best-in-class RSV & Universal Flu subunit vaccines
Vaccines
Funding History
13Total raised:$16.8M
Seed$5MJun 15, 2023
Grant$985KMar 23, 2022
Seed$5MMar 15, 2022
Grant$989KMar 4, 2021